Crying Over Stark Differences: Resource Disparity and Therapeutic Drug Monitoring

Jane E Carland^{1

2}, Jana Stojanova¹, Cindy Lau^{3

4}, Richard O Day^{1

2

5}, Deborah J E Marriott^{2

6}

Affiliations

¹ Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
² School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, NSW, Australia.
³ Department of Pharmacy, St Vincent's Hospital, Darlinghurst, NSW, Australia.
⁴ School of Pharmacy, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
⁵ School of Medical Sciences, UNSW Sydney, NSW, Australia; and.
⁶ Department of Clinical Microbiology and Infectious Diseases, St Vincent's Hospital, Darlinghurst, NSW.

Editorial

Jane E Carland et al. Ther Drug Monit. 2024.

. 2024 Jun 1;46(3):415-416.

doi: 10.1097/FTD.0000000000001185. Epub 2024 Feb 1.

Jane E Carland^{1

2}, Jana Stojanova¹, Cindy Lau^{3

4}, Richard O Day^{1

2

5}, Deborah J E Marriott^{2

6}

¹ Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, NSW, Australia.
² School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, NSW, Australia.
³ Department of Pharmacy, St Vincent's Hospital, Darlinghurst, NSW, Australia.
⁴ School of Pharmacy, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
⁵ School of Medical Sciences, UNSW Sydney, NSW, Australia; and.
⁶ Department of Clinical Microbiology and Infectious Diseases, St Vincent's Hospital, Darlinghurst, NSW.

No abstract available

Conflict of interest statement

The authors declare no conflict of interest.

Why is the Implementation of Beta-Lactam Therapeutic Drug Monitoring for the Critically Ill Falling Short? A Multicenter Mixed-Methods Study.
Barreto EF, Chitre PN, Pine KH, Shepel KK, Rule AD, Alshaer MH, Abdul Aziz MH, Roberts JA, Scheetz MH, Ausman SE, Moreland-Head LN, Rivera CG, Jannetto PJ, Mara KC, Boehmer KR. Barreto EF, et al. Ther Drug Monit. 2023 Aug 1;45(4):508-518. doi: 10.1097/FTD.0000000000001059. Epub 2023 Mar 21. Ther Drug Monit. 2023. PMID: 37076424 Free PMC article.

1. Barreto EF, Chitre PN, Pine KH, et al. Why is the implementation of beta-lactam therapeutic drug monitoring for the critically ill falling short? A multicenter mixed-methods study. Ther Drug Monit. 2023;45:508–518.
1. Yager RC, Taylor N, Stocker SL, et al. Would they accept it? An interview study to identify barriers and facilitators to user acceptance of a prescribing advice service. BMC Health Serv Res. 2022;22:514.
1. Carland JE, Elhage T, Baysari MT, et al. Would they trust it? An exploration of psychosocial and environmental factors affecting prescriber acceptance of computerised dose-recommendation software. Br J Clin Pharmacol. 2021;87:1215–1233.
1. Abdulla A, van den Broek P, Ewoldt TMJ, et al. Barriers and facilitators in the clinical implementation of beta-lactam therapeutic drug monitoring in critically ill patients: a critical review. Ther Drug Monit. 2022;44:112–120.
1. Gatti M, Cojutti PG, Bartoletti M, et al. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Crit Care. 2022;26:178.